Advances in the application of Let-7 microRNAs in the diagnosis, treatment and prognosis of leukemia

Oncol Lett. 2022 Jan;23(1):1. doi: 10.3892/ol.2021.13119. Epub 2021 Nov 2.

Abstract

The lethal-7 (Let-7) family of microRNAs (miRNAs) controls the process of development and differentiation, but is also related to the occurrence of tumors and a poor prognosis of patients with tumors. Thus, a more comprehensive exploration of its functions will provide further insights into these processes, and may promote the diagnosis and treatment of tumors. Leukemia is a type of progressive malignant disease, and its pathogenesis involves a variety of epigenetic factors. Amongst the several related epigenetic factors, the Let-7 miRNAs are an important family of molecules that play a crucial role in maintaining a variety of critical biological processes, including development, differentiation and proliferation. In the present study, the role of Let-7 as a tumor suppressor gene and oncogene is reviewed, and the complex regulatory functions of several Let-7 family members in different subtypes of leukemia are described. The current body of knowledge thus far indicates that Let-7 is not only a potential diagnostic and prognostic marker of leukemia, but also a potential therapeutic target for the treatment of affected patients, with particular potential when targeted by adjuvant treatments alongside traditional treatment to improve their survival rate.

Keywords: Let-7 microRNAs; leukemia; regulatory factors; tumor therapy.

Publication types

  • Review

Grants and funding

This study was supported by The National 12th Five-Year Plan for Major New Drug Creation Science and Technology (grant no. 2013ZX09103003-002), the National 13th Five-Year Plan for Major New Drug Creation Science and Technology (grant no. 2019ZX09301-166), the National Natural Science Foundation of China (grant nos. 81101605 and 81573467), the Natural Science Foundation of Shandong (grant no. ZR2020QH160) and The Foundation for Teachers' Research Project of Jining Medical University (grant no. JYFC2019FKJ102).